Evidence map›Paper›PMID 40553176›Full record

ArticleJournal of neurology2025

Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment.

C Asteggiano, L Mazzocchi, L Farina, M Paoletti, L Barzaghi, E Caverzasi, S Parravicini, M I Dainesi, A Gardani, G Savini and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

C AsteggianoDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. asteggianocarlo@gmail.com.ORCID http://orcid.org/0000-0002-1439-3293
L MazzocchiAdvanced Imaging and Artificial Intelligence Center, IRCCS Mondino Foundation, Pavia, Italy.
L FarinaAdvanced Imaging and Artificial Intelligence Center, IRCCS Mondino Foundation, Pavia, Italy.
M PaolettiAdvanced Imaging and Artificial Intelligence Center, IRCCS Mondino Foundation, Pavia, Italy.
L BarzaghiAdvanced Imaging and Artificial Intelligence Center, IRCCS Mondino Foundation, Pavia, Italy.
E CaverzasiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
S ParraviciniIRCCS Mondino Foundation, Pavia, Italy.
M I DainesiIRCCS Mondino Foundation, Pavia, Italy.
A GardaniIRCCS Mondino Foundation, Pavia, Italy.
G SaviniDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
N BergslandBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.
E BallanteDepartment of Political and Social Sciences, University of Pavia, Pavia, Italy.
C A M Gandini Wheeler-KingshottDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
A BerardinelliIRCCS Mondino Foundation, Pavia, Italy.
A PichiecchioDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Funding

Ministero della Salute Ricerca Corrente 2022-2024National Recovery and Resilience Plan (NRRP), project MNESYS PE0000006
6 · The paper itself

Abstract

backgroundNusinersen is an approved disease-modifying therapy for spinal muscular atrophy (SMA), a rare neuromuscular disease characterized by degeneration of alpha motor neurons in the brainstem and spinal cord (SC), leading to progressive muscle atrophy and weakness. This exploratory study investigated the potential of quantitative SC magnetic resonance imaging (MRI) as a biomarker for monitoring treatment-related changes in pediatric and adult SMA patients treated with nusinersen at different disease stages.

methodsFive pediatric and three adult SMA patients underwent clinical assessments, including the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM), along with SC MRI at multiple time points (TPs) during nusinersen treatment. At each TP, total cross-sectional area (TCA), grey matter area (GM

resultsAll pediatric patients showed a progressive increase in SC TCA and GM

conclusionNusinersen showed beneficial effects in both adult and pediatric SMA patients, with more marked improvements in children. Quantitative SC MRI metrics, especially TCA and GM

Indexed as

Cervical CordMagnetic Resonance ImagingMuscular Atrophy, SpinalOligonucleotidesAdolescentAdultBiomarkersChildChild, PreschoolDisease ProgressionFemaleHumansMaleMiddle AgedYoung AdultBiomarkersnusinersenOligonucleotidesMagnetization transferNusinersen (spinraza)Quantitative magnetic resonance imagingSpinal cord MRISpinal muscular atrophy

Identifiers

PMID40553176
PMCPMC12187881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.